

Genzyme Corporation

One Kendall Square, 1400 Building, 4th Floor
Cambridge, Massachusetts 02139 U.S.A.
Telephone: (617) 252-7500
Facsimil : (617) 252-7977

LEGAL DEPARTMENT

Robert J. Cobert,
Senior Patent Counsel
Direct Dial: (617) 591-5823

FAX RECEIVED
DEC 04 2002
GROUP 1600

Facsimile

To: Examiner R. Shukla**From:** Robert J. Cobert

Art Unit 1632

Fax: 703-308-4242**Pages:** 2 + cover**Phone:****Date:** December 3, 2002**Re:** USSN 09/784,563**CC:**

NOTICE OF CONFIDENTIALITY

This transmission is intended only for the addressee(s) listed above, and may contain information that is confidential or privileged. If you are not the addressee, any use, disclosure, copying or communication of the contents of this transmission is prohibited. If this message was received in error, please call Carol Celata at (617) 591-5852 or Debbie Gunkel at (617) 252-7653 and we will arrange for the return of this message at no cost to you.

#9
EX (4) 7
Electron

Dkt. No. 5026

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Chester Li, et al.

Examiner: R. Shukla

USSN: 09/784,563

Art Unit: 1632

Filed: February 15, 2001

Title: Genetic Modification of the Lung as a Portal For Gene Delivery

Assistant Commissioner For Patents
Washington, DC 20231

December 3, 2002

Sir:

**Facsimile Amendment and Response To July 3, 2002
Office Action And Petition For Four Month Extension Of Time**

This paper is filed by facsimile in response to the July 3, 2002 Office Action issued by Examiner Shukla in connection with the above-identified application. A response to the Office Action was due on August 3, 2002. Applicants hereby request a four month extension of time, from August 3, 2002 to December 3, 2002. Authorization is given to charge Deposit Account No. 07-1074 in the amount of the fee for a four month extension of time. With the extension of time a response is due on December 3, 2002 and therefore this response is being filed timely.

REMARKS

Claims 1-15 are pending in the subject application. Examiner Shukla has indicated that claims 1-15 are subject to restriction and election of species.

In response to the Office Action, applicants elect Group I, claims 1-10 for prosecution.

In addition, applicants elect the species of treatment of Fabry's Disease in response to the

01 FC:1254

1440.00 CH

12/09/2002 TTAB1 00000005 071074 09784563


Response To July 3, 2002 Office Action
USSN 09/784,563
Page 2

Examiner's requirement for the election of a species. Currently claims 1, 2 and 5 of Group I read on the elected species. Applicants understand that if a generic claim is allowed, claims to additional species will be considered as provided by 37 CFR 1.141.

If a telephone interview would be of assistance, Examiner Shukla is invited to telephone applicants' undersigned attorney at the number listed below.

No fee, other than the fee for a four month extension of time, is required in connection with this filing. However, if any additional fee is required, authorization is given to charge the amount of the additional fee to Deposit Account No. 07-1074.

Respectfully submitted,



Robert J. Cobert
Reg. No. 36,108
Genzyme Corporation
One Kendall Square
Cambridge, MA 02139
617-591-5823

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. (703) 308-4242) on December 3, 2002.


Robert J. Cobert